Progress in frontotemporal dementia research

American Journal of Alzheimer's Disease and other Dementias

Volumn 28, Issue 1, 2013, Pages 15-23

  Wang, Xinling ^a,b   Shen, Yuedi ^c   Chen, Wei ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c HANGZHOU NORMAL UNIVERSITY   (China)

Author keywords

Alzheimer's; Animal models; Frontotemporal dementia; Genetics; Pathology; Therapy

Indexed keywords

APOLIPOPROTEIN E; ARIPIPRAZOLE; CHROMATIN MODIFYING PROTEIN 2B; FLUOXETINE; FLUVOXAMINE; FUSED IN SARCOMA PROTEIN; MEMANTINE; OLANZAPINE; PAROXETINE; PIRACETAM; PROGRANULIN; PROTEIN; SERTRALINE; TAR DNA BINDING PROTEIN; TAU PROTEIN; TRAZODONE; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN;

BEHAVIOR DISORDER; CLINICAL RESEARCH; COMPULSION; DRUG DOSE INCREASE; EATING DISORDER; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; IMPULSIVENESS; LANGUAGE DISABILITY; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; REVIEW; SIDE EFFECT; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84876468085     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317512467681     Document Type: Review

References (103)

1. Bird T, Knopman D, VanSwieten J, et al. Epidemiology and genetics of frontotemporal dementia/Pick's disease. Ann Neurol. 2003;54(Suppl 5):S29-S31. (Pubitemid 36760151)
2. Feldman H, Levy AR, Hsiung GY, et al. A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. Neuroepidemiology. 2003;22(5): 265-274. (Pubitemid 36993907)
3. Boxer AL, Miller BL. Clinical features of frontotemporal dementia. Alzheimer Dis Assoc Disord. 2005;(19 suppl 1):S3-S6. (Pubitemid 44378500)
4. Mackenzie IR, NeumannM, Bigio EH, et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol. 2009;117(1):15-18.
5. Harciarek M, Jodzio K. Neuropsychological differences between frontotemporal dementia and Alzheimer's disease: a review. Neuropsychol Rev. 2005;15(3):131-145. (Pubitemid 41674441)
6. Mackenzie IR, Rademakers R. The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics. 2007;8(4):237-248. (Pubitemid 47624449)
7. Galimberti D, Scarpini E. Genetics of frontotemporal lobar degeneration. Front Neurol. 2012;3:52.
8. Ahmed Z, Sheng H, Xu YF, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol. 2010;177(1):311-324.
9. Seripa D, Bizzarro A, Panza F, et al. The APOE gene locus in frontotemporal dementia and primary progressive aphasia. Arch Neurol. 2011;68(5):622-628.
10. Laws SM, Perneczky R, Drzezga A, et al. Association of the tau haplotype H2 with age at onset and functional alterations of glucose utilization in frontotemporal dementia. Am J Psychiatry. 2007;164(10):1577-1584. (Pubitemid 350069738)
11. Kowalska A. The genetics of dementias. Part 1: Molecular basis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Postepy Hig Med Dosw (Online). 2009;63(278-286).
12. Gloeckner SF, Meyne F, Wagner F, et al. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis. 2008;14(1):17-25. (Pubitemid 352039015)
13. Grossman M, Libon DJ, Forman MS, et al. Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. Arch Neurol. 2007;64(11):1601-1609. (Pubitemid 350106761)
14. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916-919. (Pubitemid 44285946)
15. Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-ositive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442(7105):920-924. (Pubitemid 44285947)
16. Borroni B, Archetti S, Alberici A, et al. Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. Neurogenetics. 2008;9(3):197-205.
17. Davion S, Johnson N, Weintraub S, et al. Clinicopathologic correlation in PGRN mutations. Neurology. 2007;69(11):1113-1121. (Pubitemid 47517556)
18. Chiang HH, Rosvall L, Brohede J, et al. Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska family. Alzheimers Dement. 2008;4(6):414-420.
19. Gijselinck I, van der Zee J, Engelborghs S, et al. Progranulin locus deletion in frontotemporal dementia. Hum Mutat. 2008;29(1): 53-58.
20. Yu CE, Bird TD, Bekris LM, et al. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol. 2010;67(2):161-170.
21. Cenik B, Sephton CF, Dewey CM, et al., Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem. 2011;286(18):16101-16108.
22. Bossu P, Salani F, Alberici A, et al. Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. J Neuroinflammation. 2011;8:65.
23. Whitwell JL, Weigand SD, Gunter JL, et al. Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN. Neurology. 2011;77(4):393-398.
24. Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol. 2011;24(6):542-549.
25. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245-256.
26. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257-268.
27. Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain. 2012;135(pt 3):794-806.
28. Kimonis VE, Fulchiero E, Vesa J, et al. VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder. Biochim Biophys Acta. 2008; 1782(12):744-748.
29. Guinto JB, Ritson GP, Taylor JP, et al. Valosin-containing protein and the pathogenesis of frontotemporal dementia associated with inclusion body myopathy. Acta Neuropathol. 2007; 114(1):55-61. (Pubitemid 47029060)
30. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36(4):377-381. (Pubitemid 38437260)
31. Liscic RM. Frontotemporal dementias: update on recent developments in molecular genetics and neuropathology. Arh Hig Rada Toksikol. 2009;60(1):117-122.
32. Davidson Y, Kelley T, Mackenzie IR, et al. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol. 2007; 113(5):521-533. (Pubitemid 46672598)
33. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130-133. (Pubitemid 44547757)
34. Kwong LK, Neumann M, Sampathu DM, et al. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol. 2007;114(1):63-70. (Pubitemid 47029061)
35. Winton MJ, Igaz LM, Wong MM, et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem. 2008;283(19):13302-13309.
36. Ayala YM, Zago P, D'Ambrogio A, et al. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008;121(pt 22):3778-3785.
37. Wang IF, Wu LS, Chang HY, et al. TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem. 2008;105(3):797-806.
38. Neumann M, Tolnay M, Mackenzie IR. The molecular basis of frontotemporal dementia. Expert Rev Mol Med. 2009;11:e23.
39. Strong MJ, Volkening K, Hammond R, et al. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci. 2007;35(2):320-327. (Pubitemid 46843567)
40. Riggi N, Cironi L, Suva ML, et al. Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET. J Pathol. 2007;213(1):4-20. (Pubitemid 47354561)
41. Andersson MK, Stahlberg A, Arvidsson Y, et al. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol. 2008;9:37.
42. Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-43. Cell. 2009;136(6):1001-1004.
43. Yang S, Warraich ST, Nicholson GA, et al. Fused in sarcoma/translocated in liposarcoma: a multifunctional DNA/RNA binding protein. Int J Biochem Cell Biol. 2010;42(9): 1408-1411.
44. Zinszner H, Sok J, Immanuel D, et al. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J Cell Sci. 1997;110(pt 15):1741-1750. (Pubitemid 27352853)
45. Wang X, Arai S, Song X, et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature. 2008;454(7200):126-130. (Pubitemid 351934270)
46. Fujii R, Okabe S, Urushido T, et al. The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology. Curr Biol. 2005;15(6):587-593. (Pubitemid 40413401)
47. Fujii R, Takumi T. TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines. J Cell Sci. 2005; 118(pt 24):5755-5765. (Pubitemid 43079269)
48. Lanson NA, Jr, Pandey UB. FUS-related proteinopathies: lessons from animal models. Brain Res. 2012;1462:44-60.
49. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119(1):1-4.
50. Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet. 2005;37(8):806-808. (Pubitemid 41077105)
51. van der Zee J, Urwin H, Engelborghs S, et al. CHMP2B C-Truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Hum Mol Genet. 2008;17(2):313-322.
52. Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol. 2007;114(1):5-22. (Pubitemid 47029055)
53. Neumann M, Rademakers R, Roeber S, et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132(pt 11):2922-2931.
54. Seelaar H, Klijnsma KY, de Koning I, et al. Frequency of ubiquitin and FUS-ositive, TDP-43-negative frontotemporal lobar degeneration. J Neurol. 2010;257(5):747-753.
55. Josephs KA, Lin WL, Ahmed Z, et al. Frontotemporal lobar degeneration with ubiquitin-ositive, but TDP-43-negative inclusions. Acta Neuropathol. 2008;116(2):159-167.
56. Josephs KA, Holton JL, Rossor MN, et al. Neurofilament inclusion body disease: a newproteinopathy? Brain.2003;126(pt 10):2291-2303. (Pubitemid 37432372)
57. Josephs KA, Whitwell JL, Parisi JE, et al. Caudate atrophy on MRI is a characteristic feature of FTLD-FUS. Eur J Neurol. 2010;17(7):969-975.
58. Gabelle A, Roche S, Geny C, et al. Decreased sAbetaPPbeta, Abeta38, and Abeta40 cerebrospinal fluid levels in frontotemporal dementia. J Alzheimers Dis. 2011;26(3):553-563.
59. Huang C, Zhou H, Tong J, et al. FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet. 2011;7(3):e1002011.
60. Ghazi-Noori S, FroudKE,Mizielinska S, et al. Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. Brain. 2012;135(pt 3):819-832.
61. Ward ME, Miller BL. Potential mechanisms of progranulindeficient FTLD. J Mol Neurosci. 2011;45(3):574-582.
62. Yin F,DumontM,Banerjee R, et al.Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J. 2010;24(12):4639-4647.
63. Brunk UT, Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med. 2002;33(5):611-619. (Pubitemid 35245833)
64. Lewis J, McGowan E, Rockwood J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25(4):402-405. (Pubitemid 32983430)
65. Gotz J, Chen F, van Dorpe J, et al. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293(5534):1491-1495. (Pubitemid 32807681)
66. Gotz J. Tau and transgenic animal models. Brain Res Brain Res Rev. 2001;35(3):266-286. (Pubitemid 32566200)
67. Gilley J, Seereeram A, Ando K, et al. Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a "P301L" tau knockin mouse. Neurobiol Aging. 2012;33(3):621.
68. Ittner LM, Fath T, Ke YD, et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci U S A. 2008;105(41):15997-16002.
69. Boxer AL, Boeve BF. Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis Assoc Disord. 2007;21(4):S79-87. (Pubitemid 350307449)
70. Lopez-Pousa S, Calvo-Perxas L, Lejarreta S, et al. Use of antidementia drugs in frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2012;27(4):260-266.
71. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66(1):17-22. (Pubitemid 43739585)
72. Swartz JR, Miller BL, Lesser IM, et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58(5):212-216. (Pubitemid 27242008)
73. Mendez MF. Frontotemporal dementia: therapeutic interventions. Front Neurol Neurosci. 2009;24:168-178.
74. Fellgiebel A, Muller MJ, Hiemke C, et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry. 2007;8(2):123-126. (Pubitemid 46681093)
75. Moretti R, Torre P, Antonello RM, et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18(4):205-214. (Pubitemid 37010729)
76. Doody RS. Cholinesterase inhibitors and memantine: best practices. CNS Spectr. 2008;13(10 suppl 16):34-35.
77. Daiello LA, Ott BR, Festa EK, et al. Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease. J Clin Psychopharmacol. 2010;30(3):245-251.
78. Prvulovic D, Hampel H, Pantel J. Galantamine for Alzheimer's disease. Expert Opin Drug Metab Toxicol. 2010;6(3):345-354.
79. Wilkinson D, Schindler R, Schwam E, et al. Effectiveness of donepezil in reducing clinical worsening in patients with mild-To-moderate alzheimer's disease. Dement Geriatr Cogn Disord. 2009;28(3):244-251.
80. MendezMF, Shapira JS,McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15(1):84-87. (Pubitemid 46106094)
81. Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25(2):178-185. (Pubitemid 351196131)
82. O'Brien JT, Burns A. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(8):997-1019.
83. Mecocci P, Bladstrom A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry. 2009;24(5):532-538.
84. Ferris S, Ihl R, Robert P, et al. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients. Alzheimers Dement. 2009;5(5):369-374.
85. Grossberg GT, Pejovic V, Miller ML, et al. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2009;27(2):164-172.
86. Franceschi M, Anchisi D, Pelati O, et al. Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann Neurol. 2005;57(2):216-225. (Pubitemid 40179860)
87. Ishikawa H, Shimomura T, Shimizu T. Stereotyped behaviors and compulsive complaints of pain improved by fluvoxamine in two cases of frontotemporal dementia. Seishin Shinkeigaku Zasshi. 2006;108(10):1029-1035.
88. Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49(1):13-19. (Pubitemid 35477963)
89. Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004;172(4):400-408. (Pubitemid 38650975)
90. Lebert F, Stekke W, Hasenbroekx C, et al. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17(4):355-359. (Pubitemid 38721158)
91. Pijnenburg YA, Sampson EL, Harvey RJ, et al. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry. 2003;18(1):67-72. (Pubitemid 36131229)
92. Bei H, Ross L, Neuhaus J, et al. Off-label medication use in frontotemporal dementia. Am J Alzheimers Dis Other Demen. 2010;25(2):128-133.
93. Alonso-Navarro H, Jabbour-Wadih T, Ayuso-Peralta L, et al. The neurochemistry and neuropharmacology of frontotemporal dementia. Rev Neurol. 2006;42(9):556-561. (Pubitemid 47378360)
94. ProcterAW, QurneM, Francis PT. Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord. 1999;(10 suppl 1):80-84. (Pubitemid 29348621)
95. Di Lazzaro V, Pilato F, Dileone M, et al. In vivo cholinergic circuit evaluation in frontotemporal and Alzheimer dementias. Neurology. 2006;66(7):1111-1113. (Pubitemid 44044806)
96. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004; 21(14):931-937. (Pubitemid 39626373)
97. Hirano S, Shinotoh H, Shimada H, et al. Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Brain. 2010;133(pt 7):2058-2068.
98. WuTY,ChenCP. Dual action ofmemantine in Alzheimer disease: a hypothesis. Taiwan J Obstet Gynecol. 2009;48(3):273-277.
99. Martinez-Coria H, Green KN, Billings LM, et al. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol. 2010;176(2):870-880.
100. Boxer AL, Lipton AM,Womack K, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23(3):211-217.
101. Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2007;21(2):164-166. (Pubitemid 46878979)
102. Diehl-Schmid J, Forstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry. 2008;23(7):754-759.
103. Vercelletto M, Boutoleau-Bretonniere C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis. 2011;23(4):749-759.